搜索
Oruka Therapeutics Inc
ORKA添加自选
61.930USD
-1.970-3.08%
收盘 05/15, 16:00（美东）报价延迟15分钟
3.74B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.08%
5天
-4.12%
1月
-5.52%
6月
+128.69%
今年开始到现在
+104.32%
1年
+554.65%
TradingKey Oruka Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Oruka Therapeutics Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名93/382位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价135.69。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Oruka Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Oruka Therapeutics Inc亮点
亮点风险
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-25.97，处于3年历史低位
机构加仓
最新机构持股56.79M股，环比增加10.95%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值599.96K
活跃度增加
近期活跃度增加，过去20天平均换手率1.26
分析师目标
根据
14
位分析师
强力买入
评级
135.692
目标均价
+114.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Oruka Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Oruka Therapeutics Inc简介
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
公司代码ORKA
公司Oruka Therapeutics Inc
CEOKlein (Lawrence Otto)
网址https://orukatx.com/
相关品种
